BACKGROUND: Recommendations for high-risk human papillomavirus (HR-HPV) testing as an adjunct to cytology for cervical cancer screening differ by age group, because HR-HPV tests lack adequate specificity in women aged <30. Here, we assess age-group differences in HPV types and other risk factors for cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+) versus CIN0-2 in women from four colposcopy clinics. METHODS: Women ages 18 to 69 (n = 1,658) were enrolled and completed structured interviews to elicit data on behavioral risk factors prior to their examinations. HPV genotyping was done on exfoliated cervical cell samples. We estimated relative risks (RR) for HPV types and cofactors for CIN3+, overall and stratified by age group. RESULTS: After 2 years of follow-up, we identified 178 CIN3+, 1,305 CIN0-2, and 175 indeterminate outcomes. Nonvaccine HR-HPV types were only associated with CIN3+ among women ≥ 30 (RR = 2.3, 95% CI: 1.5-3.4; <30: RR = 0.9). Among all HR-HPV-positive women, adjusting for age, significant cofactors for CIN3+ included current smoking (RR = 1.5), former smoking (RR = 1.8), regular Pap screening (RR = 0.7), current regular condom use (RR = 0.5), and parity ≥ 5 (RR = 1.6, P(trend) for increasing parity = 0.07). However, the parity association differed by age group (≥ 30: RR = 1.8, P(trend) = 0.008; <30: RR = 0.9; P(trend) =.55). CONCLUSION: Subgroup variation by age in the risk of CIN3+ points to the importance of the timing of exposures in relation to CIN3+ detection. IMPACT: Future screening strategies need to consider natural history and secular trends in cofactor prevalence in the pursuit of appropriately sensitive and specific screening tools applied to appropriate age groups.
BACKGROUND: Recommendations for high-risk human papillomavirus (HR-HPV) testing as an adjunct to cytology for cervical cancer screening differ by age group, because HR-HPV tests lack adequate specificity in women aged <30. Here, we assess age-group differences in HPV types and other risk factors for cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+) versus CIN0-2 in women from four colposcopy clinics. METHODS:Women ages 18 to 69 (n = 1,658) were enrolled and completed structured interviews to elicit data on behavioral risk factors prior to their examinations. HPV genotyping was done on exfoliated cervical cell samples. We estimated relative risks (RR) for HPV types and cofactors for CIN3+, overall and stratified by age group. RESULTS: After 2 years of follow-up, we identified 178 CIN3+, 1,305 CIN0-2, and 175 indeterminate outcomes. Nonvaccine HR-HPV types were only associated with CIN3+ among women ≥ 30 (RR = 2.3, 95% CI: 1.5-3.4; <30: RR = 0.9). Among all HR-HPV-positive women, adjusting for age, significant cofactors for CIN3+ included current smoking (RR = 1.5), former smoking (RR = 1.8), regular Pap screening (RR = 0.7), current regular condom use (RR = 0.5), and parity ≥ 5 (RR = 1.6, P(trend) for increasing parity = 0.07). However, the parity association differed by age group (≥ 30: RR = 1.8, P(trend) = 0.008; <30: RR = 0.9; P(trend) =.55). CONCLUSION: Subgroup variation by age in the risk of CIN3+ points to the importance of the timing of exposures in relation to CIN3+ detection. IMPACT: Future screening strategies need to consider natural history and secular trends in cofactor prevalence in the pursuit of appropriately sensitive and specific screening tools applied to appropriate age groups.
Authors: Ralph P Insinga; Gonzalo Perez; Cosette M Wheeler; Laura A Koutsky; Suzanne M Garland; Sepp Leodolter; Elmar A Joura; Daron G Ferris; Marc Steben; Darron R Brown; Elamin H Elbasha; Jorma Paavonen; Richard M Haupt Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-06 Impact factor: 4.254
Authors: Philip E Castle; Mark Schiffman; Cosette M Wheeler; Nicolas Wentzensen; Patti E Gravitt Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-07 Impact factor: 4.254
Authors: Ana Cecilia Rodríguez; Mark Schiffman; Rolando Herrero; Allan Hildesheim; Concepción Bratti; Mark E Sherman; Diane Solomon; Diego Guillén; Mario Alfaro; Jorge Morales; Martha Hutchinson; Hormuzd Katki; Li Cheung; Sholom Wacholder; Robert D Burk Journal: J Natl Cancer Inst Date: 2010-02-15 Impact factor: 13.506
Authors: Francesca M Carozzi; Maria L Tornesello; Elena Burroni; Giovanna Loquercio; Giuseppe Carillo; Claudio Angeloni; Aurora Scalisi; Rosalba Macis; Francesco Chini; Franco M Buonaguro; Paolo Giorgi Rossi Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-09 Impact factor: 4.254
Authors: Martyn Plummer; Rolando Herrero; Silvia Franceschi; Chris J L M Meijer; Peter Snijders; F Xavier Bosch; Silvia de Sanjosé; Nubia Muñoz Journal: Cancer Causes Control Date: 2003-11 Impact factor: 2.506
Authors: Carolina Porras; Ana Cecilia Rodríguez; Allan Hildesheim; Rolando Herrero; Paula González; Sholom Wacholder; Robert D Burk; Mark Schiffman Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-03 Impact factor: 4.254
Authors: Paolo Dalla Palma; Paolo Giorgi Rossi; Guido Collina; Anna Maria Buccoliero; Bruno Ghiringhello; Eliana Gilioli; Gian Libero Onnis; Daniela Aldovini; Giuseppe Galanti; Gianpiero Casadei; Mirella Aldi; Vito V Gomes; Pamela Giubilato; Guglielmo Ronco Journal: Am J Clin Pathol Date: 2009-07 Impact factor: 2.493
Authors: Sophia S Wang; Rosemary E Zuna; Nicolas Wentzensen; S Terence Dunn; Mark E Sherman; Michael A Gold; Mark Schiffman; Sholom Wacholder; Richard A Allen; Ingrid Block; Kim Downing; Jose Jeronimo; J Daniel Carreon; Mahboobeh Safaeian; David Brown; Joan L Walker Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-01 Impact factor: 4.254
Authors: Lauren M Schwartz; Philip E Castle; Stephen Follansbee; Sylvia Borgonovo; Barbara Fetterman; Diane Tokugawa; Thomas S Lorey; Vikrant V Sahasrabuddhe; Patricia Luhn; Julia C Gage; Teresa M Darragh; Nicolas Wentzensen Journal: J Infect Dis Date: 2013-08-01 Impact factor: 5.226
Authors: Carole Fakhry; Tim Waterboer; William H Westra; Lisa M Rooper; Melina Windon; Tanya Troy; Wayne Koch; Christine G Gourin; Noemi Bender; Siddhartha Yavvari; Ana P Kiess; Brett A Miles; William R Ryan; Patrick K Ha; David W Eisele; Gypsyamber D'Souza Journal: Oral Oncol Date: 2019-12-24 Impact factor: 5.337
Authors: D Tasic; I Lazarevic; A Knezevic; L Tasic; A Pikula; Z Perisic; T Jovanovic; M Cupic Journal: Epidemiol Infect Date: 2018-06-20 Impact factor: 4.434
Authors: Mariano Guardado-Estrada; Eligia Juárez-Torres; Edgar Román-Bassaure; Ingrid Medina-Martinez; Ana Alfaro; Rosa Elba Benuto; Michael Dean; Nicolás Villegas-Sepulveda; Jaime Berumen Journal: PLoS One Date: 2014-10-08 Impact factor: 3.240
Authors: Oscar Del Moral-Hernández; Daniel Hernández-Sotelo; Luz Del Carmen Alarcón-Romero; Miguel Angel Mendoza-Catalán; Eugenia Flores-Alfaro; Yaneth Castro-Coronel; Julio Ortiz-Ortiz; Marco Antonio Leyva-Vázquez; Carlos Ortuño-Pineda; Wendy Castro-Mora; Berenice Illades-Aguiar Journal: BMC Cancer Date: 2021-01-07 Impact factor: 4.430